For research use only. Not for therapeutic Use.
VPC-70619 is a potent, orally active N-Myc inhibitor. VPC-70619 blocks the N-Myc-Max heterocomplex from binding to DNA E-boxes and demonstrated strong inhibition activity against N-Myc-dependent cell lines as well as high bioavailability in both oral and intraperitoneal administration[1].
| Catalog Number | I044030 |
| CAS Number | 2361742-30-3 |
| Synonyms | 3-chloro-4-cyano-N’-[4-cyano-2-(trifluoromethyl)phenyl]benzohydrazide |
| Molecular Formula | C16H8ClF3N4O |
| Purity | ≥95% |
| InChI | InChI=1S/C16H8ClF3N4O/c17-13-6-10(2-3-11(13)8-22)15(25)24-23-14-4-1-9(7-21)5-12(14)16(18,19)20/h1-6,23H,(H,24,25) |
| InChIKey | XTKCWHGATOSBEH-UHFFFAOYSA-N |
| SMILES | C1=CC(=C(C=C1C#N)C(F)(F)F)NNC(=O)C2=CC(=C(C=C2)C#N)Cl |
| Reference | [1]. Ton AT, et al. Development of VPC-70619, a Small-Molecule N-Myc Inhibitor as a Potential Therapy for Neuroendocrine Prostate Cancer. Int J Mol Sci. 2022;23(5):2588. Published 2022 Feb 26. |
